USPTO Examiner BROWN KYLE MARTZ - Art Unit 3794

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18750990DEVICES AND SYSTEMS FOR ABLATION THERAPYJune 2024November 2025Abandon1620NoNo
18046472DEVICES, SYSTEMS, AND METHODS OF APPLYING NANO-DIMENSIONED ICE PARTICLES TO ANIMAL TISSUESOctober 2022September 2025Abandon4410NoNo
17949735INTRAVITAL COOLING DEVICESeptember 2022September 2025Abandon3610NoNo
17911981BODY ELECTRODE FOR RECORDING ELECTRO-PHYSIOLOGICAL SIGNALSSeptember 2022July 2025Abandon3410NoNo
17840699CATHETER DEVICE AND CATHETERJune 2022March 2026Abandon4520NoNo
17707119CONDUCTIVE PADMarch 2022July 2025Abandon4010NoNo
17636882DISPOSABLE SPIRAL ELECTRODE FOR FETAL SCALPFebruary 2022July 2025Abandon4110NoNo
17636231COLD AND HOT COMPRESS SYSTEMFebruary 2022April 2025Abandon3810NoNo
17634350Multi-Terminal Sensors for Thread-Based CircuitryFebruary 2022September 2025Abandon4410NoNo
17629059WEARABLE BIOPOTENTIAL PATCH WITH METHOD TO OPTIMIZE COMFORT AND ACCURACYJanuary 2022November 2025Abandon4520NoNo
17624364DEVICES, SYSTEMS AND METHODS FOR ASSISTANCE OF BALLOON ABLATIONJanuary 2022August 2025Abandon4420NoNo
17520239HEATED SLEEVE FOR A PROSTHETIC LIMBNovember 2021February 2026Abandon5230NoNo
17494432SURGICAL METHODS FOR CONTROL OF ONE VISUALIZATION WITH ANOTHEROctober 2021March 2026Abandon5330YesNo
17492659ELECTROCHEMICAL THERAPY OF CANCEROUS TUMORS BASED ON INTRA-THERAPEUTICAL IMPEDANCE MONITORINGOctober 2021November 2024Abandon3810NoNo
17492654ELECTROCHEMICAL THERAPY OF CANCEROUS TUMORS BASED ON INTRA-THERAPEUTICAL IMPEDANCE MONITORINGOctober 2021November 2024Abandon3710NoNo
17460438SYSTEM AND METHODS FOR INSERTION DEPTH TRACKINGAugust 2021August 2025Abandon4840NoNo
17398185Wearable TagsAugust 2021April 2025Abandon4420YesNo
17418068DETACHABLE SURGICAL INSTRUMENTJune 2021October 2024Abandon4010NoNo
17287708PLASMA TREATMENT DEVICEApril 2021December 2024Abandon4410NoNo
17237146METHOD OF PERFORMING CRYONEUROLYSISApril 2021April 2025Abandon4820YesNo
17286843ELECTRODE AND USES THEREOFApril 2021September 2024Abandon4110NoNo
17217905DEVICES AND SYSTEMS FOR ABLATION THERAPYMarch 2021March 2024Allow3500NoNo
17208252METHOD FOR TREATMENT OF ERECTILE DYSFUNCTIONMarch 2021May 2024Allow3810NoNo
17204348MEDICAL DEVICE, CONTROL METHOD, AND COMPUTER-READABLE STORAGE MEDIUMMarch 2021January 2025Allow4620YesNo
17173230ELECTROPHYSIOLOGY CATHETER DESIGNFebruary 2021June 2024Allow4010NoNo
16952186Vein Heating AssemblyNovember 2020April 2025Abandon5320NoNo
17064513BIOCOMPATIBLE IMPLANTABLE ELECTRODEOctober 2020November 2024Abandon4910NoNo
17019984BEVELED END EFFECTOR ASSEMBLYSeptember 2020November 2025Abandon6061YesNo
16990981TERAHERTZ HEALTHY ROSARY STRUCTUREAugust 2020September 2024Abandon4920NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner BROWN, KYLE MARTZ - Prosecution Strategy Guide

Executive Summary

Examiner BROWN, KYLE MARTZ works in Art Unit 3794 and has examined 18 patent applications in our dataset. With an allowance rate of 22.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner BROWN, KYLE MARTZ's allowance rate of 22.2% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BROWN, KYLE MARTZ receive 1.89 office actions before reaching final disposition. This places the examiner in the 45% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BROWN, KYLE MARTZ is 46 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a -3.1% benefit to allowance rate for applications examined by BROWN, KYLE MARTZ. This interview benefit is in the 7% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 0.0% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 14.3% of cases where such amendments are filed. This entry rate is in the 15% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 48% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 50% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.